EARNING RECAP

Jazz Pharmaceuticals PLC

#JAZZ 2019 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q1 adjusted $3.67 est. $3.16 $508M est. $465.95M +9.28% ($140.59 closing price0 $142 $133.72 sees FY19 adjusted EPS $14.30- $15 est. $14.60, FY19 revenue $2.05-$2.13B est. $2.07B
#JAZZ 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted $3.64 est. $3.02 $476.5M est. $459.72M +7.88% ($137.83 closing price) $141.55 $137.20 sees FY19 adj. EPS $14.30-$15.00, consensus $13.98; FY19 revenue $2.05B-$2.13B est. $2.03B
Q3 adjusted EPS $3.58 vs $3.32 $469M vs $482.48M -14.60% ($140.41 closing price) $153.00 $139.33 Backs FY18 adj. EPS $12.75- $13.25 est. $13.11; lowers FY18 revenue view to $1.86B-$1.9B from $1.88B- $1.93B est. $1.92B
Q2 adjusted $3.49 est. $3.23 $500M est. $469.62M -2.40% ($175.58 closing price) $177.04 $172.50 sees FY18 (EPS & Revenue) adj. EPS $12.75 -$13.25 est. $13.09; revenue $1.88B -$1.93B est. $1.9B
#JAZZ 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q3 adjusted $3.22 vs $2.89 $411.85M vs $421M +2.70% ($136.40 closing price) $142.00 $132.52 Sees FY17 ad EPS $10.70-$11.20 vs $10.89 est
Q2 Adjusted $2.56 vs $2.75 $394.39M vs $410.08M -6.17% ($142.90 closing price) $145.24 $140.60 FY17 adj EPS view of $10.70 -$11.30 vs $11.02 est
Q1 $2.31 VS $2.34 EST $376m vs $377.02m -0.94% ($156.86 closing price) $158.49 $152.06 sees FY17 adjusted EPS $10.70-$11.30, consensus $11.12

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.